A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst? Trey Thoelcke Tue, August 11, 2026 at 3:20 PM GMT+2 3 min read BCRX AZN TAK NVDA AZN Quick Read BioCryst hit its first full year of profitability in 2025, with Q2 2026 revenue up 34% to $218 million, fueling acquisition speculation. Takeda (TAK) tops the buyer rankings as navenibart directly threatens its Takhzyro franchise; AstraZeneca (AZN) ranks second through its Alexion rare-disease platform.
Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and BioCryst Pharmaceuticals didn't make the cut. Grab the names FREE today. BioCryst Pharmaceuticals (NASDAQ:BCRX) closed at $9.84 on August 10, 2026, giving the Durham-based rare-disease specialist a market cap of roughly $2.5 billion.
Shares are up 26.2% year to date and 18.6% over one year, though still down 35.3% over five years. What changed is the P&L. 24/7 Wall St. BioCryst notched its first full year of profitability in 2025, and Q2 2026 delivered $218.25 million in revenue, up 33.6% year over year, with $98.47 million in operating income and $352.57 million in cash, cash equivalents, and short-term investments.
Mid-July takeover buzz following an acquisition in the biotech sector put BioCryst on watch lists, though no deal talks have been confirmed. Notably, BioCryst is itself an acquirer, having closed the Astria Therapeutics deal on January 23, 2026, to bring in navenibart. Why a Strategic Buyer Would Want It The prize is Orladeyo, an oral once-daily plasma kallikrein inhibitor for hereditary angioedema (HAE) that generated $158.2 million in Q2 2026 revenue, with full-year guidance of $625 million to $645 million.
Behind it sits navenibart, a long-acting injectable whose pivotal ALPHA-ORBIT enrollment completed in June, with top-line data due Q3 2027. A European licensing deal with Neopharmed Gentili worth $70 million upfront plus up to $275 million in milestones already validated the asset. Ranking the Plausible Acquirers 5.
The Horizon playbook fits, but Amgen carries $57.3 billion in debt and a Tavneos withdrawal overhang, limiting appetite. 4. Deep rare-disease bench and a fresh $2.2 billion Dynavax acquisition, but focus is Dupixent and immunology under a new CEO. Grab the names FREE today. 3.
Extract — continue reading at the source.
